UCI Therapeutics Overview

  • Year Founded
  • 2020

Year Founded

  • Status
  • Private

  • Employees
  • 4

Employees

  • Latest Deal Type
  • Early Stage VC

  • Latest Deal Amount
  • $3.31M

  • Investors
  • 14

UCI Therapeutics General Information

Description

Developer of cell-based therapeutics designed to address unmet medical needs through advanced biotechnology. The company focuses on the research and development of cell therapy products by utilizing cells as the fundamental structural and functional units of living organisms, applying modern bioengineering techniques including cell isolation, culture, and modification processes to create treatments targeting various diseases, enabling patients and healthcare providers in the regenerative medicine space to access novel cell-based therapeutic options aimed at restoring or replacing damaged cells and tissues for improved clinical outcomes.

Contact Information

Website
www.uci-therapeutics.co.kr
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • Number 644, 87, Cheongam-ro
  • Nam-gu
  • Pohang, Gyeongsang
  • South Korea
+82
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Vertical(s)
Life Sciences, Oncology
Corporate Office
  • Number 644, 87, Cheongam-ro
  • Nam-gu
  • Pohang, Gyeongsang
  • South Korea
+82

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

UCI Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
4. Early Stage VC 24-May-2022 $3.31M Completed Pre-Clinical Trials
3. Accelerator/Incubator 01-Apr-2021 Completed Pre-Clinical Trials
2. Seed Round 28-Feb-2021 Completed Pre-Clinical Trials
1. Accelerator/Incubator Completed Pre-Clinical Trials
To view UCI Therapeutics’s complete valuation and funding history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Request a free trial

UCI Therapeutics Patents

  • 13

    Total Documents Applications and Grants

  • Total Patents Families

  • Granted

  • 6

    Pending

  • Expiring in next 12 mo

UCI Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2026177560-A1 Natural killer cells expressing dual-targeting chimeric antigen receptors for cd19 and cd22, and uses thereof Pending 21-Feb-2025
WO-2025220989-A1 Feeder cells for enhancing natural killer cell amplification and transduction efficiency Pending 16-Apr-2024
AU-2024201132-A1 Anti-mesothelin antibodies and uses thereof Pending 20-Sep-2023
EP-4527407-A1 Anti-mesothelin antibodies and uses thereof Pending 20-Sep-2023
US-20250092154-A1 Anti-mesothelin antibodies and uses thereof Pending 20-Sep-2023 A61K39/001102
To view UCI Therapeutics’s complete patent history, request access »

UCI Therapeutics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

UCI Therapeutics Investors (14)

Investor Name Investor Type Holding Investor Since Participating Rounds
Colopl Next Corporate Venture Capital Minority
Coropranext Other Minority
DT & Investment Corporate Venture Capital Minority
Gyeongnam Venture Investment Venture Capital Minority
MMS Ventures (Korea) Venture Capital Minority
You’re viewing 5 of 14 investors. Get the full list »

Ready to get started?

Request a free trial

UCI Therapeutics FAQs

  • When was UCI Therapeutics founded?

    UCI Therapeutics was founded in 2020.

  • Where is UCI Therapeutics headquartered?

    UCI Therapeutics is headquartered in Pohang, South Korea.

  • What is the size of UCI Therapeutics?

    UCI Therapeutics has 4 total employees.

  • What industry is UCI Therapeutics in?

    UCI Therapeutics’s primary industry is Drug Discovery.

  • Is UCI Therapeutics a private or public company?

    UCI Therapeutics is a Private company.

  • What is UCI Therapeutics’s current revenue?

    The current revenue for UCI Therapeutics is .

  • How much funding has UCI Therapeutics raised over time?

    UCI Therapeutics has raised $3.31M.

  • Who are UCI Therapeutics’s investors?

    Colopl Next, Coropranext, DT & Investment, Gyeongnam Venture Investment, and MMS Ventures (Korea) are 5 of 14 investors who have invested in UCI Therapeutics.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process